JP7595945B2 - Ｃｉｃ－１塩化物チャネル阻害剤の調製のためのプロセス - Google Patents

Ｃｉｃ－１塩化物チャネル阻害剤の調製のためのプロセス Download PDF

Info

Publication number
JP7595945B2
JP7595945B2 JP2021569300A JP2021569300A JP7595945B2 JP 7595945 B2 JP7595945 B2 JP 7595945B2 JP 2021569300 A JP2021569300 A JP 2021569300A JP 2021569300 A JP2021569300 A JP 2021569300A JP 7595945 B2 JP7595945 B2 JP 7595945B2
Authority
JP
Japan
Prior art keywords
phenoxy
dihydroisoxazol
bromo
butoxy
propanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537493A (ja
JP2022537493A5 (https=
Inventor
ケリー，ニコラス
マッケンジー，マイケル，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NMD Pharma AS
Original Assignee
NMD Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NMD Pharma AS filed Critical NMD Pharma AS
Publication of JP2022537493A publication Critical patent/JP2022537493A/ja
Publication of JP2022537493A5 publication Critical patent/JP2022537493A5/ja
Application granted granted Critical
Publication of JP7595945B2 publication Critical patent/JP7595945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021569300A 2019-06-19 2020-06-19 Ｃｉｃ－１塩化物チャネル阻害剤の調製のためのプロセス Active JP7595945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19181262 2019-06-19
EP19181262.7 2019-06-19
PCT/EP2020/067065 WO2020254554A1 (en) 2019-06-19 2020-06-19 Process for the preparation of clc-1 chloride channel inhibitors

Publications (3)

Publication Number Publication Date
JP2022537493A JP2022537493A (ja) 2022-08-26
JP2022537493A5 JP2022537493A5 (https=) 2023-06-27
JP7595945B2 true JP7595945B2 (ja) 2024-12-09

Family

ID=66999603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569300A Active JP7595945B2 (ja) 2019-06-19 2020-06-19 Ｃｉｃ－１塩化物チャネル阻害剤の調製のためのプロセス

Country Status (18)

Country Link
US (1) US12221425B2 (https=)
EP (1) EP3986878B1 (https=)
JP (1) JP7595945B2 (https=)
KR (1) KR102900834B1 (https=)
CN (1) CN113993852B (https=)
AR (1) AR119198A1 (https=)
AU (1) AU2020298092B2 (https=)
BR (1) BR112021025588A2 (https=)
CA (1) CA3137672A1 (https=)
ES (1) ES3000437T3 (https=)
HU (1) HUE069104T2 (https=)
IL (1) IL287901B2 (https=)
MX (1) MX2021013507A (https=)
PL (1) PL3986878T3 (https=)
SG (1) SG11202111122RA (https=)
TW (1) TWI849152B (https=)
WO (1) WO2020254554A1 (https=)
ZA (1) ZA202107653B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4593829A1 (en) 2022-09-30 2025-08-06 NMD Pharma A/S Compositions and methods for treating myasthenia gravis
WO2024180199A1 (en) 2023-03-02 2024-09-06 Nmd Pharma A/S Compositions and methods for treating charcot–marie–tooth disease
JP2026508357A (ja) 2023-03-02 2026-03-10 エヌエムディー ファーマ エー／エス 脊髄性筋萎縮症を処置するための組成物及び方法
EP4731200A1 (en) 2023-06-20 2026-04-29 NMD Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202341A1 (en) 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
JP7310071B2 (ja) 2017-12-14 2023-07-19 エヌエムディー ファーマ エー／エス 神経筋障害の治療のための化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
GB0524428D0 (en) * 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
WO2009097970A1 (de) * 2008-02-05 2009-08-13 Sanofi-Aventis Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
JP2015505560A (ja) * 2012-02-03 2015-02-23 ゾエティス・エルエルシー 抗寄生虫薬としてのキラルイソオキサゾリンアゼチジン誘導体の製造法
US10385028B2 (en) * 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202341A1 (en) 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
JP7310071B2 (ja) 2017-12-14 2023-07-19 エヌエムディー ファーマ エー／エス 神経筋障害の治療のための化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nippon Kagaku Kaishi，1972年，Vol.1972, No.8，pp.1452-1457，DOI:10.1246/nikkashi.1972.1452

Also Published As

Publication number Publication date
EP3986878A1 (en) 2022-04-27
HUE069104T2 (hu) 2025-02-28
BR112021025588A2 (pt) 2022-02-01
IL287901A (en) 2022-01-01
PL3986878T3 (pl) 2025-01-20
EP3986878C0 (en) 2024-09-25
CN113993852A (zh) 2022-01-28
TWI849152B (zh) 2024-07-21
US12221425B2 (en) 2025-02-11
KR102900834B1 (ko) 2025-12-16
AU2020298092A1 (en) 2021-11-18
CN113993852B (zh) 2024-12-17
SG11202111122RA (en) 2021-11-29
MX2021013507A (es) 2021-12-10
TW202115003A (zh) 2021-04-16
AU2020298092A8 (en) 2025-04-24
IL287901B2 (en) 2025-02-01
CA3137672A1 (en) 2020-12-24
WO2020254554A1 (en) 2020-12-24
ES3000437T3 (en) 2025-02-28
JP2022537493A (ja) 2022-08-26
IL287901B1 (en) 2024-10-01
AU2020298092B2 (en) 2025-09-25
ZA202107653B (en) 2023-05-31
EP3986878B1 (en) 2024-09-25
KR20220022895A (ko) 2022-02-28
AR119198A1 (es) 2021-12-01
US20220298124A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP7595945B2 (ja) Ｃｉｃ－１塩化物チャネル阻害剤の調製のためのプロセス
TWI345562B (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
CN115697971A (zh) 环丁基二氢喹啉磺酰胺化合物
JP2009221204A (ja) Ｐｐａｒアゴニスト活性を有する誘導体
WO1995024397A1 (de) 3,5-disubstituierte und 3,4,5-trisubstituierte 2-isoxazoline und isoxazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SU1241986A3 (ru) Способ получени производных бензамида,их гидрохлоридов или оптических изомеров
BR112017010471B1 (pt) Compostos de di-hidropirimidin-2-ona, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
Erhardt et al. Conformational analogs of dopamine. Synthesis and pharmacological activity of (E)-and (Z)-2-(3, 4-dihydroxyphenyl) cyclopropylamine hydrochlorides
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
JP7662196B2 (ja) 神経筋障害の治療のための化合物
HK40068865B (en) Process for the preparation of clc-1 chloride channel inhibitors
HK40068865A (en) Process for the preparation of clc-1 chloride channel inhibitors
EP3939976B1 (en) Prodrug of caspase inhibitor
KR100758317B1 (ko) 몰폴린-2-온 유도체를 포함하는 ｔ-형 칼슘 채널 차단용조성물
US20230034132A1 (en) Crystal form as inhibitor of acc1 and acc2, and preparation method therefor and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241120

R150 Certificate of patent or registration of utility model

Ref document number: 7595945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150